Biopharmaceuticals

Results: 91



#Item
61Michael Hill, et al. v. Accentia Biopharmaceuticals, Inc., et al. 13-CV[removed]Order

Michael Hill, et al. v. Accentia Biopharmaceuticals, Inc., et al. 13-CV[removed]Order

Add to Reading List

Source URL: securities.stanford.edu

Language: English - Date: 2015-02-05 17:18:37
62Angebot/Offered	place(s)		 1. Stellentitel/ Offer title: Particle-based formulation of biopharmaceuticals (postgraduate, Ph.D. student) 2. Fraunhofer Forschungsinstitut/ Research Institute Name des Instituts/ Name of Res

Angebot/Offered place(s) 1. Stellentitel/ Offer title: Particle-based formulation of biopharmaceuticals (postgraduate, Ph.D. student) 2. Fraunhofer Forschungsinstitut/ Research Institute Name des Instituts/ Name of Res

Add to Reading List

Source URL: www.igb.fraunhofer.de

Language: English - Date: 2015-01-15 07:30:06
63Production and Control of Biosimilars versus Innovators Antonio da Silva, Head Preclinical Development Hexal / Sandoz Biopharmaceuticals Lisbon, 03 April 2013 © 2013 Hexal AG, All rights reserved. All trademarks are the

Production and Control of Biosimilars versus Innovators Antonio da Silva, Head Preclinical Development Hexal / Sandoz Biopharmaceuticals Lisbon, 03 April 2013 © 2013 Hexal AG, All rights reserved. All trademarks are the

Add to Reading List

Source URL: www.egagenerics.com

Language: English - Date: 2014-12-27 09:48:37
64Investigational Biopharmaceuticals  1 2

Investigational Biopharmaceuticals 1 2

Add to Reading List

Source URL: www.igb.fraunhofer.de

Language: English - Date: 2015-01-15 18:12:12
65Investigational Biopharmaceuticals  1 2

Investigational Biopharmaceuticals 1 2

Add to Reading List

Source URL: www.item.fraunhofer.de

Language: English - Date: 2015-01-15 09:49:15
66New Option Listings - September 30, 2014 Exchange/Memo ID:[removed]ONN / OCC ID: Memo Description

New Option Listings - September 30, 2014 Exchange/Memo ID:[removed]ONN / OCC ID: Memo Description

Add to Reading List

Source URL: boxexchange.com

Language: English - Date: 2014-09-30 14:11:31
67Oct 27-29, 2014  Nigel Rulewski TENTATIVE SCIENTIFIC PROGRAM Eminent Speakers

Oct 27-29, 2014 Nigel Rulewski TENTATIVE SCIENTIFIC PROGRAM Eminent Speakers

Add to Reading List

Source URL: www.pharmaceuticalconferences.com

Language: English - Date: 2014-10-15 07:40:23
68Light Scattering for the Masses™ Protein Aggregate Removal with the DynaPro DLS Plate Reader he presence of aggregation in immunoglobulin biopharmaceuticals is a significant concern during all phases of drug developmen

Light Scattering for the Masses™ Protein Aggregate Removal with the DynaPro DLS Plate Reader he presence of aggregation in immunoglobulin biopharmaceuticals is a significant concern during all phases of drug developmen

Add to Reading List

Source URL: www.wyatt.com

Language: English - Date: 2012-02-24 16:46:35
69Comprehensive structural characterization of biopharmaceuticals by top-down mass spectrometry and hydrogen/deuterium exchange: implication for biosimilars Jingxi Pan, Derek Smith, Christoph H. Borchers UVic-Genome BC Pro

Comprehensive structural characterization of biopharmaceuticals by top-down mass spectrometry and hydrogen/deuterium exchange: implication for biosimilars Jingxi Pan, Derek Smith, Christoph H. Borchers UVic-Genome BC Pro

Add to Reading List

Source URL: www.proteincentre.com

Language: English - Date: 2014-06-23 05:00:11
70Collaborating for Cures Leveraging Global Public-Private Partnerships to Accelerate Biopharmaceuticals Development First Joint IMI & C-Path Forum on the Value of PPPs Thursday 7 March 2013 – Brussels, Belgium The Shera

Collaborating for Cures Leveraging Global Public-Private Partnerships to Accelerate Biopharmaceuticals Development First Joint IMI & C-Path Forum on the Value of PPPs Thursday 7 March 2013 – Brussels, Belgium The Shera

Add to Reading List

Source URL: c-path.org

Language: English - Date: 2014-02-20 17:49:57